You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
"Best Provider" Winner,
2019 Waters Rankings Awards:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
Relmada Therapeutics raises $115M from stock offering
COVID-19 Pandemic Likely To Cause US Telemedicine Boom
Gauging Supply Chain Risk In Volatile Times
Cannabis: Hashing Out a Budding Industry
IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help
Relmada Therapeutics Inc.
The New York-based pharmaceutical company offered 3,833,334 shares at $30 apiece, including 500,000 shares as part of underwriters' overallotment option.
Relmada intends to use the gross proceeds from the offering to fund the research and development of its treatment-resistant depression drug REL-1017, or dextromethadone, and for general corporate purposes.
Jefferies, SVB Leerink and Guggenheim Securities acted as joint book-running managers for the offering.